Press Releases 

Helomics adds Ventana ALK (D5F3) to Biomarker Test Menu

Helomics has added the Ventana ALK (D5F3) CDx Assay to its test menu and becomes one of only three sites offering the assay in the United States. Visit: https://usinfo.roche.com/alk for more information. The Ventana ALK (D5F3) CDx Assay is an FDA approved test which functions as a companion diagnostic to aid in the identification of ALK positive lung cancer patients who are eligible for treatment with Pfizer’s FDA approved therapy XALKORI® (crizotinib). Lung cancer remains the leading cause of cancer deaths, representing 12.9% of all new cancer cases and 1.6 million deaths worldwide. For a subset of non-small cell lung cancer patients, the use of this assay represents an opportunity to ini

Helomics® Corporation and MDNA Life Sciences, Inc. Announce an Agreement to Commence a Multi-Faceted

Companies intend to collaborate regarding sales and marketing, clinical lab testing, and research and development PITTSBURGH AND WEST PALM BEACH– January 12, 2017 - Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, and MDNA Life Sciences, Inc. (MDNA), the molecular diagnostics company pioneering the development of liquid biopsy tests based on the mitochondrial genome, today announced the beginning of a broad strategic relationship. As part of this collaboration, Helomics will promote MDNA’s Prostate Core Mitomic Test™ and its liquid biopsy Prostate Mitomic Tes

CEO Gerald Vardzel to Present at 9th Annual Biotech Showcase on January 9, 2017

PITTSBURGH – January 05, 2017 - Helomics® Corporation, a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, today announced that CEO Gerald Vardzel will present at the 9th Annual Biotech Showcase™ on Monday, January 9, 2017 at 10:45 a.m. Pacific Time. The conference will take place at the Hilton San Francisco Union Square, San Francisco, CA. Mr. Vardzel will discuss the new strategic focus of the Helomics laboratories and the company’s product enhancement capabilities including ex-vivo, live-cell tumor growth and how these platforms can be utilized by industry clients to fulfill specific and uniq

Archive
 Follow Us
  • LinkedIn Social Icon
  • Facebook Basic Square
  • Twitter Basic Square

© 2020 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon